What are the side effects of Panitumumab?

Panitumumab is indicated for the treatment of metastatic colorectal cancer ( span>mCRC), can be treated as monotherapy after disease progression after prior chemotherapy containing fluoropyrimidine, oxaliplatin, and irinotecan, or in combination with FOLFOX as first-line therapy.

In monotherapy with panitumumab, the most common adverse reactions(≥20%) are rash of various manifestations, paronychia, fatigue, nausea, and diarrhea. The most common (>5%) serious adverse reactions are worsening of systemic health and intestinal obstruction. The most commonly reported adverse reactions leading to discontinuation are worsening of systemic health and intestinal obstruction. In combination therapy with panitumumab, the most commonly reported adverse reactions (≥20%) were diarrhea, stomatitis, mucosal inflammation, fatigue, paronychia, anorexia, hypomagnesemia, hypokalemia, rash, acneiform dermatitis, pruritus, and dry skin. Serious adverse reactions were diarrhea and dehydration. Common adverse reactions (≥1%) leading to patient discontinuation included rash, paresthesia, fatigue, diarrhea, acneiform dermatitis, and hypersensitivity reactions.

It is understood that the original version of panitumumab has not yet been launched in China, and therefore it has not been covered by medical insurance. The price of the Hong Kong original version of panitumumab sold in Hong Kong, China100mg/5mL may be around RMB 9,000 (the price may fluctuate due to exchange rates). There are currently no generic drugs of Panitumumab on the market. If a patient has a need to purchase Panitumumab, please consult a medical consultant for specific prices and more drug information.